Renovo is a privately held pharmaceutical company specializing in the commercialization of pharmaceutical cocrystals as an enabling technology for improved drug delivery. Renovo identifies new, patentable, crystalline solid forms of active pharmaceutical ingredients (APIs) that can significantly improve physical properties. The improvedphysical properties can lead to improved drug product performance, for example, improved bioavailability. Renovo partners with leading pharmaceutical companies who share the vision of bringing improved pharmaceutical products to the marketplace using cocrystal technology.
Renovo Research
- Digital Health Community Organization - Pharmaceutical Company
Services Types
- Outsourcing Services
Locations
CEO Contact Information
Scott
Childs
President and Chief Scientific Officer
Last updated on 10/09/2023